FIELD: biotechnology.
SUBSTANCE: fusion protein is produced which contains the MUC1 antigen having an amino acid sequence that is at least 85% identical to the sequence of SEQ ID NO: 25 or at least 95% identical to the positions 92-566 of the sequence of SEQ ID NO: 25, and where MUC1 antigen contains 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 of the following amino acids L184, Y232, L233, V240, V241, L242, Y483, V497, L335, F536 and Y551.
EFFECT: invention allows to effectively treat Mucin-1-expressing carcinomas, and also to prevent their metastatic progression.
14 cl, 3 dwg, 5 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| YEAST-BASED IMMUNOTHERAPY FOR CHORDOMA | 2014 |
|
RU2679806C2 |
| IMMUNOTHERAPEUTIC COMPOSITIONS BASED ON YEAST WITH BRACHYURY | 2012 |
|
RU2619850C2 |
| YEAST-BASED IMMUNOTHERAPEUTIC COMPOSITIONS WITH BRACHYURY | 2012 |
|
RU2690180C2 |
| ANTI-TUMOUR ANTIGEN ANTIBODY AND METHODS OF APPLICATION | 2011 |
|
RU2598711C2 |
| ANTIBODIES SPECIFIC TO TUMOUR AND USE THEREOF | 2011 |
|
RU2595403C2 |
| GLYCAN-DEPENDENT IMMUNOTHERAPY MOLECULES | 2016 |
|
RU2754661C2 |
| CANCER TREATMENT USING CHIMERIC ANTIGEN-SPECIFIC RECEPTOR BASED ON HUMANISED ANTI-EGFRvIII ANTIBODY | 2014 |
|
RU2708032C2 |
| PHOSPHODIESTERASE 4D7 AS PROSTATE CANCER MARKER | 2010 |
|
RU2651474C2 |
| MODIFIED EXOTOXIN A PSEUDOMONADES | 2014 |
|
RU2687143C2 |
| TREATING CANCER BY HUMANISED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | 2014 |
|
RU2711975C2 |
